In the current study, we analyzed the methylation levels of LMX1A, SOX1, and ZNF177 to elucidate novel changes in the methylation levels of genes in CRC and determined that the novel four-gene methylation panel, which includes LMX1A, SOX1, ZNF177, and NKX6.1, could discriminate the outcomes of CRC patients. This evidence concerns the gene LMX1A and colorectal carcinoma.